Articles related to Hematology/Oncology

UnitedHealthcare’s decision to bundle G2211 into E/M payments for commercial plans signifies a shift in reimbursement strategies that oncologists need to address promptly.

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.

Lisocabtagene maraleucel offers a new treatment option for patients with CLL who have progressed on both BTK and BCL2 inhibitors, addressing an important unmet need in this patient population.

Nearly 70% of 340B contract pharmacies are now associated with pharmacy benefit managers, potentially shifting the program’s focus away from its original intent of supporting safety-net providers.

The loss of two oncology residents in a plane crash has left a significant void in cancer care at a major oncology center in Paraná, Brazil, highlighting the critical role of specialized medical professionals in smaller communities.

AL amyloidosis can present with distinctive periorbital signs, including petechiae and waxy eyelid papules, which may worsen with trauma.